

POEM - Patient Orientated Eczema Measure

Category

Healthcare Tools

View online



PLEASE REGISTER & LOGIN TO THIS MICRA GATEWAY PLATFORM TO PLACE AN ORDER.

The Patient Oriented Eczema Measure (POEM) is a simple, validated self-report questionnaire used for monitoring atopic eczema severity. It records seven symptoms shown to be important to patients. It is widely used in paper and electronic form for assessing and tracking eczema activity, both in clinical trials and in normal clinical practice. POEM is recommended by the National Institute for Health and Care Excellence (NICE) for assessing the severity of atopic dermatitis in NHS practice and has been recommended by the international Harmonising Outcome Measures for Eczema (HOME) group as a core outcome measure for eczema trials and for routine clinical practice.

About using POEM

1. POEM is free to use for non-commercial use, including public healthcare (government-funded), academic studies, and personal use (please visit

https://www.nottingham.ac.uk/research/groups/cebd/resources/poem.aspx). You do not need a license to use POEM for non-commercial use or to create a translation for non-commercial use. To help us tracking the impact of the non-commercial use of the POEM instrument, please place the non-commercial use request in the Centre for Evidence Based Dermatology (CEBD) webpage or send us an email with details of how you plan to use the scale (cebd@nottingham.ac.uk).

- 2. Since September 2022, commercial use of POEM (e.g. commercial clinical trials) has required a fee. It is downloadable for commercial use exclusively via this website. If you have a query regarding the nature of your usage, then please get in touch. Commercial use of POEM implies that you agree to the Terms and Conditions that will download alongside POEM through this website.
- 3. Further information about how POEM was developed, translations available and best practice for its use is available from the CEBD <u>webpage</u>.
- 4. The University of Nottingham is the copyright holder of the English-language version, and any available related translated version(s) of POEM, as may be amended from time to time. This licence and the payment on the order screen covers the use of the English-language and any related translated version(s) of POEM that you add to the specific order (please note, translated versions are optional and may be selected in "Add-on" section). If you require versions of POEM in different languages that are not listed in the "Add-on" section, you will be able to request permission to produce and use your own translations during the ordering process.

- 5. POEM is available commercially on a per patient basis (e.g. if a clinical trial has 50 enrolled patients, 50 'users' must be purchased), regardless of the number of data collection time points for each participant. When selecting the number of 'users' on the payment page, make this equal to the number of enrolled patients. If more patients enrol after initial purchase, please return and purchase the additional number of patients.
- 6. Please note that we do not accept changes to our standard Terms and Conditions other than in exceptional circumstances.
- 7. Contact:
- For queries regarding non-commercial use, POEM scale, and technical issue: cebd@nottingham.ac.uk.
- For queries regarding commercial use: brian.sze@nottingham.ac.uk / madhuri.raju@nottingham.ac.uk
- For queries regarding license terms and legal issue: riane.samms@nottingham.ac.uk
- For queries regarding invoice and payment: simon.holmes@nottingham.ac.uk
 - 8. Payment

Please complete the order through this website and note the order reference.

• To request an invoice and pay by bank transfer:

An invoice with payment details will be issued after placing the order in this website.

• To pay by card:

An invoice will still need to be generated, which can then be paid via the University of Nottingham online store. The link will be provided in the invoice.

Frequently Asked Questions (FAQ)

1. How have the translations been produced?

All procedures were performed in accordance with current industry standards and FDA guidance. The translation procedures are listed below:

- Two independent forward translations
- One harmonized forward translation
- One independent back-translation
- Reconciliation of back-translation and harmonized translation
- Review of back-translation by Survey Research Expert

2. I ordered POEM previously and received permission to generate my own translations. Do I now need to add translations to my order or can I re-use the ones I have previously created?

If you previously obtained the University's approval to create your own POEM translations and produced them under an earlier order, you may continue to use those versions without paying the translation fee on future orders. Please list the languages you will use in each new order and for each translation, confirm whether you already hold permission and will re-use your own

translation or whether you wish to order the University's translation.

3. Can I re-use translations purchased under a previous order for subsequent orders placed after add-on translations are implemented?

Yes. If you previously obtained the POEM translations under an earlier order, you may continue to use those versions without paying the translation fee on future orders. Please list the languages you will use in each new order and confirm that you will re-use those languages where applicable.

4. Is ordering the English version mandatory, and is the translation fee per patient?

The English version remains the mandatory instrument and is required for all commercial orders. Translations can be added as optional "add-on".

- The licence fee for the English version remains £14 per patient/participant.
- Where translations are required and added as an add-on, a one-off £75 per language applies in addition to the £14 per-patient fee. If you need a language not currently listed as an add-on (or prefer to produce your own set), please indicate this in your order; we will provide specific permission for you to make those additional translations yourself.

5. What if the language I need isn't on the add-on list? Can I produce my own translation even if it is on the list?

Licensees can notify us via their order if they require a language which isn't included currently as an 'add-on' (or prefer to undertake their own set) and that we will grant specific permission for them to undertake that/those additional translation(s). No translation fee applies when the licensee generates the translation. Please note the University does not review or validate licenseegenerated translations and bears no liability for their use within your clinical trial.

<u>6. My order predates the add-on translation implementation. Can I just pay the translation fee now and receive translations for that earlier order?</u>

No. Translated versions are only available for orders placed after the add-on implementation date. We cannot provide translated versions for earlier commercial orders due to differences in the applicable licence terms.

7. Where can I find the user instruction or user manual for POEM scale?

There is "Instructions for use" at the second page of the English version of POEM. Further technical information related to POEM scale can be found in the CEBD webpage.

References

- 1. Charman C, Venn A, Williams HC.(2004), The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective., Arch Dermatol, 140, 1513-1519
- 2. Charman CR, Venn AJ, Ravenscroft JC, Williams HC.(2013), Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchorbased methods., Br J Dermatol., 169(6), 1326–1332
- 3. Spuls PI, Gerbens LA, Simpson E, Apfelbacher CJ, Chalmers JR, Thomas KS, Prinsen CA, von Kobyletzki LB, Singh JA, Williams HC, Schmitt J, HOME initiative collaborators(2016), POEM a core instrument to measure symptoms in clinical trials: a HOME statement., Br J Dermatol
- 4. E. Grinich, J. Schmitt, D. Küster, P.I. Spuls, H.C. Williams, J.R. Chalmers, K.S. Thomas, C. Apfelbacher, C.A.C. Prinsen, M. Furue, B. Stuart, B. Carter and E. Simpson.(2018), Standardized Reporting of the Eczema Area and Severity Index (EASI) and the Patient-Oriented Eczema Measure (POEM): A Recommendation by the Harmonising Outcome Measures for Eczema (HOME) Initiative., 10.1111/bjd.16732
- 5. Schram ME, Spuls PI, Leeflang MM, Lindeboom R, Bos JD, Schmitt(2016), The Patient-Oriented Eczema Measure in young children: responsiveness and minimal clinically important difference., Allergy
- Schram ME, Spuls PI, Leeflang MM, Lindeboom R, Bos JD, Schmitt J(2012), EASI, (objective)
 SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference., Allergy, 67(1), 99-106
- 7. Howells L, Ratib S, Chalmers JR, Bradshaw L, Thomas KS; CLOTHES trial team(2018), How should minimally important change (MIC) scores for the Patient Oriented Eczema Measure (POEM) be interpreted? A validation using varied methods., Br J Dermatol.
- 8. L. Howells, S. Gran, J. R. Chalmers, B. Stuart, M. Santer, L. Bradshaw, D. M. Gaunt, M. J. Ridd, L. A. A. Gerbens, P. I. Spuls, C. Huang, N. A. Francis, K. S. Thomas.(2021), Do patient characteristics matter when calculating sample size for eczema clinical trials? L., Skin Health and Dis., e42